No Prescription |
 |
 | ||
|
Diamide Imodium |
|
| ||
No Prescription » Prescription Drugs 6 » Diamide Imodium This medication is used to treat sudden diarrhea (including traveler's diarrhea). It works by slowing down the movement of the gut. This decreases the number of bowel movements and makes the stool less watery. Loperamide is also used to reduce the amount of discharge in patients who have undergone an ileostomy. It is also used to treat on-going diarrhea in people with inflammatory bowel disease.Indications:DIAMIDE is indicated for the symptomatic control of acute and chronic diarrhoea. In patients with an ileostomy it can be used to reduce the number and volume of stools and to harden their consistency.Dosage and Administration:ADULTS AND CHILDREN OVER 12 YEARS OF AGEAcute diarrhoea: the initial dose is 2 capsules; followed by 1 capsule after every subsequent loose stool.Chronic diarrhoea: the initial dose is 2 capsules daily; this initial dose will be adjusted until 1-2 solid stools a day are obtained which is usually achieved with a maintenance dose of 1-6 capsules daily.The maximum dose for acute and chronic diarrhoea is 8 capsules daily. Buy Diamide Imodium and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About Diamide Imodium: Product Type: Prescription Drugs 6 Diamide ( Imodium Kaopectate 1-D Maalox Anti-Diarrheal Pepto Diarrhea Control Generic Loperamide ) Diamide (Imodium Kaopectate 1-D Maalox Anti-Diarrheal Pepto Diarrhea Control Generic Loperamide) Imodium Kaopectate 1-D Maalox Anti-Diarrheal Pepto Diarrhea Control Generic Loperamide 2mg 10 tablets 30(3 x 10) Tablets Imodium Kaopectate 1-D Maalox Anti-Diarrheal Pepto Diarrhea Control Generic Loperamide Diamide
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
